Prostate cancer (hormone-refractory) - docetaxel
Docetaxel for the treatment of hormone refractory prostate cancer
| Guidance type: Technology appraisal |
| Date issued: June 2006 |
We will consult on our review plans for this guidance in June 2009. |
| Reference: TA101 |
SummaryDocetaxel is recommended as a possible treatment for men with hormone-refractory metastatic prostate cancer.
NICE does not recommend using docetaxel again if the disease comes back after the first course of treatment has finished. |
| Top |
DocumentsFor healthcare professionals
For patients, carers and the public
Background information |
Implementing this guidanceAny further information NICE has produced to help the NHS implement this guideline locally is linked to below: |
| Top |
